Quote:
In mid-June, Catalent and AstraZeneca reached a deal for finish-fill duties at the Anagni site, with Catalent pledging to produce "hundreds of millions of doses" beginning in August 2020 and potentially running through March 2022 if the vaccine receives full regulatory approval.

Monday, J&J signed a five-year supply deal with Maryland-based Emergent BioSolutions to produce even more of its COVID-19 shot. The first two years of that deal are valued at $480 million, with doses provided as needed in the final three years.

As the initial step in what was pitched as the "first in a series" of manufacturing deals in March, J&J tapped Emergent to help boost production of its shot, which the company hopes to move into phase 1/2 trials later this month.

As part of the deal, J&J pledged to expand its own capacity for producing the vaccine with Emergent sharing its "molecule-to-market" manufacturing know-how. Emergent also reserved capacity at its Bayview facility in Baltimore to support a potential commercial rollout of J&J's shot beginning as early as 2021, should it nab an approval.

https://www.fiercepharma.com/manufacturing/j-...n-facility

BASICALLY J&J, Catalent and Emergent are working together on J&J vaccine. REASON thats important Catelent bought out biopark where Doc works. President is visiting Maryland to visit Emergent factory on Wednesday.

Quote:
UM BioPark Tenant Acquired for $1.2 Billion
April 16, 2019 | By Laura Lee

Paragon Bioservices, Inc., the University of Maryland BioPark’s largest tenant and one of its fastest-growing biotechnology companies, is celebrating another success with the announcement that it has entered into a definitive agreement under which Catalent, Inc., a New Jersey-based contract drug manufacturer, will acquire Paragon for $1.2 billion.

https://www.umaryland.edu/news/archived-news/...ired-f.php